PF-07872411 / Pfizer - LARVOL DELTA

A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults (clinicaltrials.gov) - P1 | N=90 | Completed | Sponsor: Pfizer | Active, not recruiting ➔ Completed

Pneumococcal vaccines • Trial completion • Infectious Disease • Pneumococcal Infections

A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults (clinicaltrials.gov) - P1 | N=90 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting | N=150 ➔ 90 | Trial completion date: Nov 2024 ➔ Jul 2024 | Trial primary completion date: Nov 2024 ➔ Jul 2024

Enrollment change • Enrollment closed • Pneumococcal vaccines • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults. (clinicaltrials.gov) - P1 | N=150 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • Pneumococcal vaccines • Infectious Disease • Pneumococcal Infections

A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults. (clinicaltrials.gov) - P1 | N=150 | Not yet recruiting | Sponsor: Pfizer

New P1 trial • Pneumococcal vaccines • Infectious Disease • Pneumococcal Infections